Table 1.
Clinical and demographic characteristics of patients with metastatic CRPC treated with ADT and abiraterone or enzalutamide from MarketScan database from January 2013 to September 2018
| Abiraterone (n = 4017) | Enzalutamide (n = 2277) | P valuea | |
|---|---|---|---|
| Age at diagnosis | |||
| Mean (SD) | 69.1 (10.8) | 69.6 (10.9) | 0.102 |
| Median (range) | 69.0 (34.0-98.0) | 70.0 (35.0-97.0) | |
| IQR | 61-78 | 61-78 | |
| DM | 201 (5.0%) | 207 (9.1%) | <0.001 |
| CKD | 183 (4.6%) | 139 (6.1%) | 0.007 |
| HTN | 1674 (41.7%) | 1181 (51.9%) | <0.001 |
| Afib | 382 (9.5%) | 278 (12.2%) | <0.001 |
| Charlson score | |||
| Mean (SD) | 8.90 (1.53) | 9.09 (1.67) | <0.001 |
| Median (range) | 9 (6-20) | 9 (6-21) | |
| Charlson score (CVD) | |||
| Mean (SD) | 0.16 (0.55) | 0.23 (0.63) | <0.001 |
| Median (range) | 0 (0-7) | 0 (0-7) | |
| Charlson score (non-CVD) | |||
| Mean (SD) | 8.74 (1.27) | 8.86 (1.35) | <0.001 |
| Median (range) | 9 (6-15) | 9 (6-17) | |
| Orchiectomy | 74 (1.8%) | 39 (1.7%) | 0.710 |
| Follow-up time | <0.001 | ||
| Mean (SD) | 16.8 (14.3) | 15.3 (12.2) | |
| Median (range) | 12.3 (0.1-72.0) | 11.7 (0.1-72.0) | |
| IQR | 6.4-23.2 | 6.2-21.3 |
ADT, androgen deprivation therapy; Afib, Atrial fibrillation; CKD, chronic kidney disease; CRPC, castrate-resistant prostate cancer; CVD, cardiovascular disease; DM, diabetes mellitus; SD, standard deviation; HTN, hypertension; IQR, interquartile range.
a
Statistical testing—numeric variables tested with analysis of variance and categorical variables tested with chi-square.